Drug combination for newly diagnosed slow-growing B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of pomalidomide, an antibody that targets a protein on B cells, and a steroid to treat slow-growing B-cell lymphomas. If you have not yet been treated and meet the health criteria, this could be an option to consider.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You need to have one of these slow-growing B-cell lymphomas: follicular lymphoma, marginal zone lymphoma, slow-growing mantle cell lymphoma, chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), or Waldenstrom macroglobulinemia.
- You must need treatment for your lymphoma now, and you must not have had any prior systemic therapy (like chemotherapy or immunotherapy) for it.
- You should be in fairly good physical condition, generally able to care for yourself (ECOG score 0-2).
- Your blood counts, liver, and kidney function need to be within certain limits, though the study allows some flexibility if abnormalities are due to lymphoma.
- No other cancer within the past 5 years, and no lymphoma in the brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of two drugs—pomalidomide (a pill that helps the immune system fight cancer) and obinutuzumab (an antibody that targets a protein on lymphoma cells). It's for people whose slow-growing lymphoma has come back or hasn't responded to standard treatments.
This trial tests a new vaccine medicine (EO2463) to treat indolent non-Hodgkin lymphoma (slow-growing lymphoma), either by itself or with other treatment. It may help your immune system recognize and attack lymphoma cells.
This study tests combining the drug lenalidomide with a standard chemotherapy regimen (G-CHOP) for people newly diagnosed with a specific type of lymphoma that has both aggressive and slow-growing parts. The goal is to see if this combination works better than standard treatment alone.
This trial tests a new drug combo for people with an aggressive type of large b-cell lymphoma. It aims to see if adding the new drug to standard chemo plus an antibody therapy is safe and works better.
This study tests a new way to treat slow-growing non-Hodgkin lymphoma that has come back or not responded to other treatments. It combines special immune cells with a targeted therapy to try to destroy cancer cells.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
Hear when a new Indolent Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.